441 related articles for article (PubMed ID: 24177492)
1. On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes.
Yellol GS; Donaire A; Yellol JG; Vasylyeva V; Janiak C; Ruiz J
Chem Commun (Camb); 2013 Dec; 49(98):11533-5. PubMed ID: 24177492
[TBL] [Abstract][Full Text] [Related]
2. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes.
Gupta G; Garci A; Murray BS; Dyson PJ; Fabre G; Trouillas P; Giannini F; Furrer J; Süss-Fink G; Therrien B
Dalton Trans; 2013 Nov; 42(43):15457-63. PubMed ID: 24022745
[TBL] [Abstract][Full Text] [Related]
4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
5. Organometallic rhodium(III) and iridium(III) cyclopentadienyl complexes with curcumin and bisdemethoxycurcumin co-ligands.
Pettinari R; Marchetti F; Pettinari C; Condello F; Petrini A; Scopelliti R; Riedel T; Dyson PJ
Dalton Trans; 2015 Dec; 44(47):20523-31. PubMed ID: 26548708
[TBL] [Abstract][Full Text] [Related]
6. Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity.
Kandioller W; Balsano E; Meier SM; Jungwirth U; Göschl S; Roller A; Jakupec MA; Berger W; Keppler BK; Hartinger CG
Chem Commun (Camb); 2013 Apr; 49(32):3348-50. PubMed ID: 23505633
[TBL] [Abstract][Full Text] [Related]
7. Similarities and differences in d
Gilewska A; Barszcz B; Masternak J; Kazimierczuk K; Sitkowski J; Wietrzyk J; Turlej E
J Biol Inorg Chem; 2019 Jun; 24(4):591-606. PubMed ID: 31115765
[TBL] [Abstract][Full Text] [Related]
8. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.
Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN
Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Characterization, and Biological Properties of Steroidal Ruthenium(II) and Iridium(III) Complexes Based on the Androst-16-en-3-ol Framework.
Koch V; Meschkov A; Feuerstein W; Pfeifer J; Fuhr O; Nieger M; Schepers U; Bräse S
Inorg Chem; 2019 Dec; 58(23):15917-15926. PubMed ID: 31714764
[TBL] [Abstract][Full Text] [Related]
10. Novel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA.
Ruiz J; Rodríguez V; Cutillas N; Samper KG; Capdevila M; Palacios Ò; Espinosa A
Dalton Trans; 2012 Nov; 41(41):12847-56. PubMed ID: 22983366
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
12. DNA binding and anti-cancer activity of redox-active heteroleptic piano-stool Ru(II), Rh(III), and Ir(III) complexes containing 4-(2-methoxypyridyl)phenyldipyrromethene.
Gupta RK; Pandey R; Sharma G; Prasad R; Koch B; Srikrishna S; Li PZ; Xu Q; Pandey DS
Inorg Chem; 2013 Apr; 52(7):3687-98. PubMed ID: 23477351
[TBL] [Abstract][Full Text] [Related]
13. [RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.
Tomaz AI; Jakusch T; Morais TS; Marques F; de Almeida RF; Mendes F; Enyedy EA; Santos I; Pessoa JC; Kiss T; Garcia MH
J Inorg Biochem; 2012 Dec; 117():261-9. PubMed ID: 22877927
[TBL] [Abstract][Full Text] [Related]
14. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
15. Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity.
Wirth S; Rohbogner CJ; Cieslak M; Kazmierczak-Baranska J; Donevski S; Nawrot B; Lorenz IP
J Biol Inorg Chem; 2010 Mar; 15(3):429-40. PubMed ID: 20091072
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Antitumor Activity Evaluation of Cyclometalated 2H-Indazole Ruthenium(II) and Iridium(III) Complexes.
Rao RN; Panchangam RL; Manickam V; Balamurali MM; Chanda K
Chempluschem; 2020 Aug; 85(8):1800-1812. PubMed ID: 32820621
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Sensitive Metal β-Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis.
Lord RM; Hebden AJ; Pask CM; Henderson IR; Allison SJ; Shepherd SL; Phillips RM; McGowan PC
J Med Chem; 2015 Jun; 58(12):4940-53. PubMed ID: 25906293
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship studies of antiplasmodial cyclometallated ruthenium(II), rhodium(III) and iridium(III) complexes of 2-phenylbenzimidazoles.
Rylands LI; Welsh A; Maepa K; Stringer T; Taylor D; Chibale K; Smith GS
Eur J Med Chem; 2019 Jan; 161():11-21. PubMed ID: 30342422
[TBL] [Abstract][Full Text] [Related]
20. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
